JPH044358B2 - - Google Patents
Info
- Publication number
- JPH044358B2 JPH044358B2 JP56149664A JP14966481A JPH044358B2 JP H044358 B2 JPH044358 B2 JP H044358B2 JP 56149664 A JP56149664 A JP 56149664A JP 14966481 A JP14966481 A JP 14966481A JP H044358 B2 JPH044358 B2 JP H044358B2
- Authority
- JP
- Japan
- Prior art keywords
- linolenic acid
- vitamin
- composition according
- acid
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 claims description 57
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims description 45
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims description 45
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims description 45
- 229960002733 gamolenic acid Drugs 0.000 claims description 45
- 235000019198 oils Nutrition 0.000 claims description 40
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 33
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical class OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 27
- 150000002632 lipids Chemical class 0.000 claims description 19
- 239000002253 acid Substances 0.000 claims description 9
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 9
- 229930195729 fatty acid Natural products 0.000 claims description 9
- 239000000194 fatty acid Substances 0.000 claims description 9
- 150000004665 fatty acids Chemical class 0.000 claims description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 8
- 240000008916 Oenothera biennis Species 0.000 claims description 8
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 8
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 235000019155 vitamin A Nutrition 0.000 claims description 8
- 239000011719 vitamin A Substances 0.000 claims description 8
- 229940045997 vitamin a Drugs 0.000 claims description 8
- 235000004496 Oenothera biennis Nutrition 0.000 claims description 7
- 235000005911 diet Nutrition 0.000 claims description 7
- 229940045761 evening primrose extract Drugs 0.000 claims description 7
- 235000008524 evening primrose extract Nutrition 0.000 claims description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 7
- 230000000378 dietary effect Effects 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 5
- 241000219925 Oenothera Species 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 150000002314 glycerols Chemical class 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 3
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 3
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 3
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 claims description 2
- 239000011585 methylcobalamin Substances 0.000 claims description 2
- 235000007672 methylcobalamin Nutrition 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical class [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims 1
- 150000003700 vitamin C derivatives Chemical class 0.000 claims 1
- 239000003921 oil Substances 0.000 description 38
- 150000003626 triacylglycerols Chemical class 0.000 description 17
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 9
- 235000020778 linoleic acid Nutrition 0.000 description 9
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 8
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 8
- 229960004488 linolenic acid Drugs 0.000 description 8
- 208000002720 Malnutrition Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000001071 malnutrition Effects 0.000 description 7
- 235000000824 malnutrition Nutrition 0.000 description 7
- 208000015380 nutritional deficiency disease Diseases 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000003833 bile salt Substances 0.000 description 5
- 229940093761 bile salts Drugs 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 230000001771 impaired effect Effects 0.000 description 5
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 4
- 239000003240 coconut oil Substances 0.000 description 4
- 235000019864 coconut oil Nutrition 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000004626 essential fatty acids Nutrition 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 229940070537 vitamin E 150 mg Drugs 0.000 description 4
- 241000925871 Nestlera biennis Species 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 235000007882 dietary composition Nutrition 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000001926 lymphatic effect Effects 0.000 description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 239000011716 vitamin B2 Substances 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 2
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 102000019280 Pancreatic lipases Human genes 0.000 description 2
- 108050006759 Pancreatic lipases Proteins 0.000 description 2
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 208000037849 arterial hypertension Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000001842 enterocyte Anatomy 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 230000020958 lipid digestion Effects 0.000 description 2
- 150000004668 long chain fatty acids Chemical class 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 229940116369 pancreatic lipase Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 229940108325 retinyl palmitate Drugs 0.000 description 2
- 235000019172 retinyl palmitate Nutrition 0.000 description 2
- 239000011769 retinyl palmitate Substances 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- 206010001367 Adrenal insufficiency Diseases 0.000 description 1
- 229910002015 Aerosil® 150 Inorganic materials 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000031968 Cadaver Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010051228 Chylothorax Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010051161 Hyperglucagonaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 206010052315 Lymphatic obstruction Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 208000035467 Pancreatic insufficiency Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 208000008425 Protein deficiency Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010041969 Steatorrhoea Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000027207 Whipple disease Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000017515 adrenocortical insufficiency Diseases 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 201000002676 cerebral atherosclerosis Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000002274 chylous ascites Diseases 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- LQJBNNIYVWPHFW-QXMHVHEDSA-N gadoleic acid Chemical compound CCCCCCCCCC\C=C/CCCCCCCC(O)=O LQJBNNIYVWPHFW-QXMHVHEDSA-N 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 1
- 208000009326 ileitis Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000004258 portal system Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000019142 school meals Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 208000001162 steatorrhea Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000012267 terminal ileitis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings or cooking oils characterised by ingredients other than fatty acid triglycerides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings or cooking oils characterised by ingredients other than fatty acid triglycerides
- A23D9/013—Other fatty acid esters, e.g. phosphatides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fats And Perfumes (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8020477A FR2490631A1 (fr) | 1980-09-24 | 1980-09-24 | Nouvelle composition lipidique utilisable en dietetique, reanimation et therapeutique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5791915A JPS5791915A (en) | 1982-06-08 |
| JPH044358B2 true JPH044358B2 (enExample) | 1992-01-28 |
Family
ID=9246241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56149664A Granted JPS5791915A (en) | 1980-09-24 | 1981-09-24 | Novel lipid composition useful for dietetics, resuscitation and treatment |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4407821A (enExample) |
| JP (1) | JPS5791915A (enExample) |
| DE (1) | DE3138088A1 (enExample) |
| FR (1) | FR2490631A1 (enExample) |
| GB (1) | GB2084172B (enExample) |
| NL (1) | NL8104348A (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5324748A (en) * | 1981-07-14 | 1994-06-28 | Efamol Limited | Method for enhancement of 1-series PG production |
| ATE24266T1 (de) * | 1982-04-16 | 1987-01-15 | Nestle Sa | Lipidhaltige zusammensetzung fuer die orale, enterale oder parenterale ernaehrung. |
| IL69782A (en) * | 1982-09-22 | 1987-12-20 | Sentrachem Ltd | Compositions for preventing cancerous conditions comprising precursors of eicosanoid mixtures and a dietary supplement containing them |
| JPS60130519A (ja) * | 1983-12-16 | 1985-07-12 | Terumo Corp | 脂肪輸液剤 |
| JPS60222418A (ja) * | 1984-04-17 | 1985-11-07 | Terumo Corp | 抗動脈硬化症製剤 |
| JPS60132916A (ja) * | 1983-12-21 | 1985-07-16 | Nisshin Oil Mills Ltd:The | 血栓症予防食品または医薬品 |
| JPS61501558A (ja) * | 1984-01-16 | 1986-07-31 | バクスタ−、トラベノ−ル、ラボラトリ−ズ、インコ−ポレイテッド | 中および長鎖トリグリセライドの非経口栄養補給 |
| US4678807A (en) * | 1984-03-01 | 1987-07-07 | Baxter Travenol Laboratories, Inc. | Method for directed visceral metabolism of medium chain triglycerides |
| GB8408974D0 (en) * | 1984-04-06 | 1984-05-16 | Efamol Ltd | Food production |
| CH663951A5 (fr) * | 1984-10-10 | 1988-01-29 | Nestle Sa | Procede d'enrichissement selectif en acides gras polyinsatures d'un melange contenant des acides gras fractions enrichies obtenues et compositions les contenant. |
| FR2574089B1 (fr) * | 1984-12-03 | 1987-04-10 | Inst Nat Sante Rech Med | Procede de production d'acides gras, en particulier d'acide g-linoleique a partir de tetrahymena, produits obtenus et preparation medicamenteuse ou alimentaire contenant de l'acide g-linolenique ou ses derives en tant qu'agent anti-agregation plaquettaire |
| JPH078803B2 (ja) * | 1986-04-25 | 1995-02-01 | 雪印乳業株式会社 | 低コレステロール血症治療剤 |
| EP0267965A1 (en) * | 1986-05-23 | 1988-05-25 | NAKANISHI, Michio | Composition containing linolenic acid compound |
| GB8621816D0 (en) * | 1986-09-10 | 1986-10-15 | Efamol Ltd | Therapeutic composition |
| IT1214018B (it) * | 1987-11-26 | 1990-01-05 | Giuliano Roberto Crema | Estensione dell'uso di un prodotto farmaceutico alimentare curativo |
| US4999380A (en) * | 1988-10-18 | 1991-03-12 | Nestec S.A. | Treatment of lipoprotein disorders associated with cholesterol metabolism |
| US5234952A (en) * | 1988-12-23 | 1993-08-10 | Nestec S.A. | Reduction of thrombogenicity with lipids of blackcurrant seed |
| CH676909A5 (enExample) * | 1988-12-23 | 1991-03-28 | Nestle Sa | |
| US5000975A (en) * | 1988-12-29 | 1991-03-19 | American Home Products Corporation | Randomized palm oil fat composition for infant formulas |
| DE3901048A1 (de) * | 1989-01-14 | 1990-07-19 | Chimicasa Gmbh | Antikachectikum |
| EP0400547A1 (en) * | 1989-06-02 | 1990-12-05 | Abbott Laboratories | Parenteral nutrition product |
| US5196198A (en) * | 1989-06-02 | 1993-03-23 | Abbott Laboratories | Parenteral nutrition product |
| ES2033193B1 (es) * | 1990-10-30 | 1994-01-16 | Ganadera Union Ind Agro | Mezcla grasa para nutricion infantil y de adultos. |
| FR2673812B1 (fr) * | 1991-03-13 | 1994-04-01 | Roussel Uclaf | Nouvelles compositions destinees a etre utilisees en dietetique et en therapeutique et renfermant une combinaison particuliere de glucides et leurs applications. |
| GB9111900D0 (en) * | 1991-06-03 | 1991-07-24 | Efamol Holdings | Fatty acid compositions |
| US5470839A (en) * | 1993-04-22 | 1995-11-28 | Clintec Nutrition Company | Enteral diet and method for providing nutrition to a diabetic |
| NL9301251A (nl) * | 1993-07-15 | 1995-02-01 | Gerard Maria Eugene Janssen | Middel ter toevoeging aan een sportdrank en het vormen van een nieuw soort sportdrank voor sportprestatieverbetering. |
| DE4405545A1 (de) * | 1994-02-22 | 1995-08-31 | Dietl Hans | Fettlösliche Vitamine enthaltende Zubereitung zur oralen Applikation |
| WO1998047486A1 (en) * | 1997-04-18 | 1998-10-29 | Taisho Pharmaceutical Co., Ltd. | Microemulsion |
| ES2252874T3 (es) * | 1997-12-12 | 2006-05-16 | Purdue Research Foundation | Utilizacion de acido linoleico conjugado para tratamiento de la diabetes mellitus tipo ii. |
| US7015249B1 (en) | 1997-12-12 | 2006-03-21 | Purdue Research Foundation | Methods and compositions for treating diabetes |
| US6107349A (en) * | 1998-04-16 | 2000-08-22 | Mantynen; Philip R. | Method and composition for treating psoriasis |
| US6835408B2 (en) | 1998-11-13 | 2004-12-28 | The Nisshin Oillio Group, Ltd. | Oil or fat composition |
| US20070179197A1 (en) * | 2000-05-01 | 2007-08-02 | Accera, Inc. | Compositions and methods for improving or preserving brain function |
| US8124589B2 (en) | 2000-05-01 | 2012-02-28 | Accera, Inc. | Use of ketogenic compounds for treatment of age-associated memory impairment |
| ES2752800T3 (es) * | 2000-05-01 | 2020-04-06 | Cerecin Inc | Uso de triglicéridos de cadena media para el tratamiento y la prevención de la enfermedad del Parkinson resultante de un metabolismo neuronal reducido |
| US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
| EP1357977B1 (en) * | 2000-09-21 | 2004-07-21 | Nutrition 21, Inc. | Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia |
| EP1392278A4 (en) * | 2001-05-14 | 2005-05-04 | Martek Biosciences Corp | PREPARATION AND USE OF A POLAR LIPIDREICH FRACTION WITH STEARIDONIC ACID AND GAMMA LINOLIC ACID FROM PLANT SEEDS AND MICROBES |
| EP1392623A4 (en) * | 2001-05-14 | 2005-05-04 | Martek Biosciences Corp | PREPARATION AND USE OF A POLAR LIPID RICH FRACTION CONTAINING HIGHLY UNSATURATED OMEGA-3 AND / OR OMEGA-6 FATTY ACIDS FROM MICROBES, SEEDS OF GENETICALLY MODIFIED PLANTS AND MARINE ORGANISMS |
| EP1481675A4 (en) * | 2002-03-04 | 2006-01-25 | Nisshin Oillio Group Ltd | MEDIUM FOR INCREASING BODY TEMPERATURE |
| JP2004075653A (ja) * | 2002-06-19 | 2004-03-11 | Nisshin Oillio Ltd | 体脂肪分解促進剤および飲食物 |
| DE10254584A1 (de) * | 2002-11-22 | 2004-06-09 | HORST HEIRLER PROJEKTE für Ernährung, Medizin, Ökologie | Verwendung von mittelkettigen Triglyceriden (MCT) zur ernährungsphysiologischen Optimierung des Fettsäurenspektrums in einem diätetischen Lebensmittel für Diabetiker |
| CN1756554A (zh) * | 2003-03-06 | 2006-04-05 | 艾克塞拉公司 | 新的化学实体和它们用于治疗代谢障碍的方法 |
| FR2860720A1 (fr) * | 2003-10-09 | 2005-04-15 | Jean Pascal Conduzorgues | Nouvelles compositions pharmaceutiques pour traiter la xerostomie et maladies similaires |
| US20050096383A1 (en) * | 2003-11-04 | 2005-05-05 | Ingvar Olafsson | Method and composition for oral cavity hygiene |
| US7175862B2 (en) * | 2004-01-28 | 2007-02-13 | Access Business Group International Llc | Method of preparing kakadu plum powder |
| EP1656934A1 (en) * | 2004-11-12 | 2006-05-17 | Cognis IP Management GmbH | Use of physiologically active fatty acids for treating lipodystrophy |
| US20060252775A1 (en) * | 2005-05-03 | 2006-11-09 | Henderson Samuel T | Methods for reducing levels of disease associated proteins |
| WO2007001883A2 (en) * | 2005-06-20 | 2007-01-04 | Accera, Inc. | Method to reduce oxidative damage and improve mitochondrial efficiency |
| HUE037129T2 (hu) * | 2005-12-15 | 2018-08-28 | Nestec Sa | Kompozíciók és eljárások agyi funkció megõrzésére |
| CA2684213A1 (en) | 2007-04-12 | 2008-10-23 | Regents Of The University Of Minnesota | Ischemia/reperfusion protection compositions and methods of using |
| US20080318909A1 (en) * | 2007-06-14 | 2008-12-25 | Sparagna Genevieve C | Use Of Linoleic Compounds Against Heart Failure |
| EP2179284B1 (en) | 2007-07-31 | 2016-09-28 | Accera, Inc. | Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function |
| JP5428107B2 (ja) * | 2007-11-27 | 2014-02-26 | 出光興産株式会社 | 扁平上皮癌細胞増殖抑制剤 |
| US8105809B2 (en) * | 2008-07-03 | 2012-01-31 | Accera, Inc. | Enzymatic synthesis of acetoacetate esters and derivatives |
| US9125881B2 (en) * | 2008-07-03 | 2015-09-08 | Accera, Inc. | Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders |
| US8183227B1 (en) | 2011-07-07 | 2012-05-22 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
| US8168611B1 (en) | 2011-09-29 | 2012-05-01 | Chemo S.A. France | Compositions, kits and methods for nutrition supplementation |
| US10307398B2 (en) | 2016-09-20 | 2019-06-04 | Regents Of The University Of Minnesota | Resuscitation composition and methods of making and using |
| WO2020052742A1 (en) * | 2018-09-11 | 2020-03-19 | Parapharm Development Limited | Capsule, tablet or pill |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3450819A (en) * | 1965-07-12 | 1969-06-17 | Drew Chem Corp | Synthetic therapeutic fat |
| GB1446431A (en) | 1972-04-20 | 1976-08-18 | Williams J | Nutritional supplement |
| FR2197605A1 (en) | 1972-09-06 | 1974-03-29 | Williams John | Foodstuff or skin nutrient to combat cholesterolaemia - contains arachidonic acid or gamma linolenic acid or esters and salts thereof |
| GB1506563A (en) * | 1974-04-25 | 1978-04-05 | Williams J | Immunosuppressive agents |
| GB1580444A (en) * | 1976-11-04 | 1980-12-03 | Bio Oil Res | Pharmaceutical compositions |
-
1980
- 1980-09-24 FR FR8020477A patent/FR2490631A1/fr active Granted
-
1981
- 1981-09-15 US US06/302,624 patent/US4407821A/en not_active Expired - Lifetime
- 1981-09-22 NL NL8104348A patent/NL8104348A/nl not_active Application Discontinuation
- 1981-09-24 GB GB8128943A patent/GB2084172B/en not_active Expired
- 1981-09-24 DE DE19813138088 patent/DE3138088A1/de active Granted
- 1981-09-24 JP JP56149664A patent/JPS5791915A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5791915A (en) | 1982-06-08 |
| DE3138088C2 (enExample) | 1992-07-30 |
| NL8104348A (nl) | 1982-04-16 |
| FR2490631B1 (enExample) | 1983-11-18 |
| DE3138088A1 (de) | 1982-05-06 |
| GB2084172A (en) | 1982-04-07 |
| FR2490631A1 (fr) | 1982-03-26 |
| US4407821A (en) | 1983-10-04 |
| GB2084172B (en) | 1984-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4407821A (en) | Lipidic compositions for use in dietetics, reanimation and therapeutics | |
| CA2069600C (en) | Fatty acid compositions | |
| EP1296670B1 (en) | Therapeutic combinations of fatty acids | |
| US5059622A (en) | Method for reducing blood pressure levels in hypertensive persons | |
| JP2004531568A (ja) | 補酵素ｑおよびエイコサペンタエン酸（ｅｐａ） | |
| CN1105016A (zh) | 甘油三酯 | |
| JP2007526943A (ja) | 構造化されたトリグリセリド類およびそれを含むエマルション類 | |
| JPH08500332A (ja) | 炎症性疾患の治療のための非経口的に投与される医薬を調製するためのエマルジョンの使用 | |
| EP2509431B1 (en) | Balanced fat composition and use thereof in a liquid nutritional composition suitable for enteral feeding | |
| CN105054025A (zh) | 一种用于炎症性肠病患者的低脂低渗低渣型肠内营养粉剂 | |
| JP4633048B2 (ja) | 日内リズム正常化組成物 | |
| JP2006083136A (ja) | ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物 | |
| EP0437520B1 (en) | Triglyceride and nutritional composition comprising such triglyceride | |
| Nishimukai et al. | Enteral administration of soyabean lecithin enhanced lymphatic absorption of triacylglycerol in rats | |
| JP4522075B2 (ja) | 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物 | |
| CN105878226A (zh) | 对白天活动量减少及/或抑郁症状具有改善作用的组合物 | |
| JPH04290821A (ja) | 液体栄養副作用の予防方法またはそれに用いる薬剤の製造方法 | |
| JP2006083134A (ja) | ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物 | |
| JPH04152861A (ja) | 栄養補給用栄養組成物 | |
| US6228367B1 (en) | Food supplement formulation | |
| Punia et al. | Mechanism of action of essential fatty acids | |
| JP4721642B2 (ja) | 肝障害を伴う肝臓疾患の予防又は改善剤 | |
| CA1334002C (en) | Essential fatty acid compositions and methods for the modulation of prostaglandin levels in mammals | |
| GB2222080A (en) | Nutritional compositions comprising polyunsaturated fatty acid salts | |
| KR20260020812A (ko) | 오메가-3 ala 성분을 함유한 씨앗오일이 첨가된 견과류 식품 제조 방법 |